HPV 16 is generally considered the more dangerous of the two types because it causes more cancers overall and is harder for the body to clear. However, the comparison isn’t straightforward: once cervical cancer develops, HPV 18 is actually linked to worse survival outcomes. Both types are high-risk and together account for about 70% of all cervical cancers, but they behave differently in ways that matter.
HPV 16 Causes More Precancerous Changes
When researchers compare how often each type leads to serious precancerous cervical lesions (called CIN 3 or worse), HPV 16 comes out ahead. Women who test positive for HPV 16 have an 8.1% absolute risk of developing these advanced lesions, compared to 6.5% for HPV 18. Both are dramatically higher than the 1.8% risk from other high-risk HPV types. Compared to someone with no HPV infection at all, testing positive for HPV 16 raises the risk of advanced precancerous changes by roughly 223 times, while HPV 18 raises it by about 177 times.
These numbers make HPV 16 the single most carcinogenic HPV type. It’s the reason screening guidelines treat a positive HPV 16 result as an immediate trigger for closer follow-up, rather than the “wait and retest” approach used for some other high-risk types.
HPV 16 Is Harder for Your Body to Clear
Most HPV infections resolve on their own, but HPV 16 hangs around longer than HPV 18. In a study of women aged 18 to 25, about 68.5% of HPV 16 infections cleared within two years, compared to 85% of HPV 18 infections. By four years, 17.9% of HPV 16 infections were still detectable, versus only 9.8% of HPV 18 infections.
This persistence matters because the longer an HPV infection sticks around, the greater the chance it will cause cell changes that lead to cancer. HPV 16’s tendency to linger is one of the main reasons it’s responsible for a larger share of HPV-related cancers across the body.
HPV 16 Dominates Cancers Beyond the Cervix
HPV doesn’t only cause cervical cancer. It’s also linked to cancers of the throat, anus, vulva, vagina, and penis. HPV 16 is overwhelmingly dominant in these other cancer sites, especially in the throat. More than 90% of HPV-driven oropharyngeal (throat) cancers are caused by HPV 16 specifically, according to researchers at Johns Hopkins.
The pattern is similar for anal cancer. In a U.S. study of invasive anal cancers, HPV 16 was found in 77.4% of cases. HPV 18 was present in only 3.4%. Together the two types accounted for nearly 80% of anal cancers, but HPV 16 carried the vast majority of that burden.
HPV 18 Is Tied to a More Aggressive Cancer Type
Here’s where HPV 18 stands out in a concerning way. Cervical cancer comes in two main forms: squamous cell carcinoma (the more common type, starting in the flat cells lining the cervix) and adenocarcinoma (starting in the glandular cells deeper inside the cervical canal). HPV 18 has a disproportionate connection to adenocarcinoma, accounting for about 37% of those cases worldwide, compared to only 12% of squamous cell carcinomas.
Adenocarcinomas are generally harder to detect through routine screening because they develop higher up in the cervical canal, where a Pap smear or visual exam may miss early changes. This means HPV 18-related cancers can sometimes be caught at a later stage.
HPV 18 Leads to Worse Survival Once Cancer Develops
Perhaps the most surprising finding for people comparing these two types: if cervical cancer does develop, patients with HPV 18 infections tend to fare worse than those with HPV 16. A systematic review and meta-analysis found that cervical cancer patients infected with HPV 18 had a 34% higher risk of dying or having their cancer progress compared to those with HPV 16. This held true for both overall survival and progression-free survival.
This likely connects to HPV 18’s association with adenocarcinoma, which tends to respond less favorably to standard treatments than squamous cell carcinoma. So while HPV 16 causes more cancer cases overall, the cancers linked to HPV 18 can be more difficult to treat successfully.
Both Types Are Equally Preventable
All available HPV vaccines target both type 16 and type 18. In people vaccinated before any HPV exposure, the vaccines are 91 to 100% effective at preventing infection with these types and 93 to 99% effective at preventing the precancerous cervical changes they cause. The three vaccine formulations (bivalent, quadrivalent, and nonavalent) perform similarly against HPV 16 and 18 specifically.
Effectiveness drops in people who have already been exposed to HPV before vaccination, but the vaccines still provide significant protection. For people not yet vaccinated, this is one area where the “which is worse” question becomes irrelevant: the same shot protects against both.
Putting It Together
If you’re looking at the full picture, HPV 16 is the bigger threat at the population level. It causes more infections that persist, leads to more precancerous changes, and is responsible for the vast majority of HPV-related cancers outside the cervix. It is the single most carcinogenic HPV type known.
HPV 18, while less common as a cancer cause, is linked to a more aggressive form of cervical cancer and worse outcomes for patients who do develop the disease. Neither type should be taken lightly, and a positive test for either one warrants close follow-up with your healthcare provider to monitor for cell changes before they progress.